NCT/Study#
NCT05859334 /
10559
A Phase 2 Study of Erdafitinib in Patients with Recurrent or Progressive IDH-Wild Type Glioma with an FGFR-TACC Gene Fusion
DISEASE GROUP:
Neuro-Oncology
current phase:
Phase II
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
